All Articles

The preliminary findings of a retrospective study that analyzed healthcare claims from the Biologics and Biosimilars Collective Intelligence Consortium’s Distributed Research Network between 2016 and 2020 indicate that utilization of biosimilar trastuzumab-anns increased over time, whereas the use of trastuzumab reference decreased.

Simulation models demonstrate substantial cost-savings realized by conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced (febrile) neutropenia prophylaxis in patients with metastatic pancreatic cancer, and that these cost-savings could be reallocated to provide access to antineoplastic treatment on a budget-neutral basis.

This past year, the COVID-19 pandemic continued to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums.

The results of a phase 3, randomized, double-blind study established the equivalence of bevacizumab reference to its biosimilar BCD-021 in terms of clinical efficacy, safety, pharmacokinetics, and immunogenicity in patients with NSCLC.

The 5-year follow-up results of a comparative phase 3 study further support the similarity of SB3 and trastuzumab reference with respect to cardiac safety profile and long-term efficacy.

The results of the randomized phase 3 TX05-03 study confirmed the therapeutic equivalence of trastuzumab reference and its biosimilar TX05 in terms of pathologic complete response, objective response rate, safety, and immunogenicity.

The findings of a survey of US oncologists indicate that practicing oncologists have gaps in their knowledge about biosimilars.

A comprehensive, team-based biosimilar adoption model in a community oncology practice demonstrated successful conversion from brand drugs to biosimilars that was associated with substantial cost-savings.

Analysis of real-world trends of biosimilar prescribing from 2019 to 2020 indicated rapid uptake of biosimilars among oncology providers, although the extent of biosimilar prescribing varied among products.

The findings of a retrospective observational study on healthcare resource utilization and cost patterns after formulary conversion to a biosimilar indicate that overall results may be driven by behavior at initial formulary switch.